PEGS Europe Keynotes |Protein and Antibody Engineering Summit

2020 Archived Content

OVERVIEW | DOWNLOAD BROCHURE | PLENARY KEYNOTE | BREAKOUT DISCUSSIONS | ATTENDEES

Monday, 9 November

14:00

Keynote Chairperson's Remarks

Janice M. Reichert, PhD, Executive Director, The Antibody Society

14:05

mAbs vs. Bugs: Antibody Therapies for Infectious Disease

Steve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKline

This year’s coronavirus pandemic has provided a stark reminder of the threat to global health posed by infectious disease and the need for new treatments. Renewed attention has been brought to the potential of antibodies as anti-infective therapeutics, which historically has been a challenging area for drug discovery. Synergies between modern vaccine development approaches and antibody discovery technologies offer new opportunities in the fight against our microbial foes.

14:30 Clinical Trials on Stimulating Innate Immunity for Type 1 Diabetes, Alzheimer's, and COVID

Denise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General Hospital

It has become apparent that perhaps in the developed world, there is less lifelong innate immunity. This is consistent with the Hygiene Hypothesis and maybe made worse by less exposure to the BCG vaccine. In this presentation we will use BCG as an example of potent innate immune stimulation from data from human clinical trials. The impact of stimulated innate immunity may have implications for infectious diseases such as COVID, for changes in metabolism related to diabetes and finally perhaps a growing human data set on benefit in Alzheimer’s disease.

14:55 LIVE PANEL DISCUSSION:

Overview of Biologic COVID-19 Interventions

Panel Moderator:

Janice M. Reichert, PhD, Executive Director, The Antibody Society

Panelists:

James E. Crowe Jr., MD, Ann Scott Carell Chair & Professor & Director, Vaccine Center, Vanderbilt University Medical Center

Michael Hust, PhD, Professor & Research Group Leader, Biotechnology, Technische Universität Braunschweig

Steve Martin, PhD, Vice President, Biopharm Discovery, GlaxoSmithKline

Denise L. Faustman, MD, PhD, Associate Professor & Director, Immunobiology Labs, Massachusetts General Hospital

15:20 Refresh Break - View Our Virtual Exhibit Hall

15:40 Problem-Solving Breakout Discussions - View Our Virtual Exhibit Hall

Join your colleagues and fellow delegates for a focused, informal discussion moderated by a member of our speaking faculty. A small group format allows participants to meet potential collaborators, share examples from their own work and discuss ideas with peers.

16:30 Close of Day

Synergistic Effect of Hydrodynamic Flow and Interfaces on Antibody Aggregation

Paolo Arosio, PhD, Assistant Professor, Chemistry & Applied Biosciences, ETH Zurich

Novel Cytokine-Grafting Technique Generates Potent Interleukin-2 Immunotherapy with Efficacy in Multiple Cancer Models

Onur Boyman, Professor & Chair, Immunology, University Hospital Zurich

ATMP Potency: Metrological Considerations

Christopher Bravery, PhD, Consulting Regulatory Scientist, Consulting on Advanced Biologicals Ltd.

Rapid and Nimble Expression and Production Tools: Lessons Learned over the Past Few Months

Nicola A. Burgess-Brown, PhD, Principal Investigator, Biotechnology, Structural Genomics Consortium

Immunologic Mechanisms and Engineering Objectives: Case Study of Anti-PD-L1 x IL-15
Daniel S. Chen, MD, PhD, CMO, IGM Biosciences

Clinical Challenges and Engineering Solutions in Cancer Immunotherapy: What Do We Need Now?
Daniel S. Chen, MD, PhD, CMO, IGM Biosciences

Antibody Discovery Is More than Just Binders

Ruud M. De Wildt, PhD, Director & Biopharm R&D Head, Lead Discovery, GlaxoSmithKline

How Stroma Targeting through a Novel FAP-Targeting ADC, OMTX705, Represents a New Treatment Alternative for Chemotherapy and Pembrolizumab-Resistant Solid Tumors